The agreement, which was entered into in June 2018, grants Gilead exclusive rights to Hookipa's TheraT and VaxWave investigational arenavirus-based immunization technologies for the development of immunotherapies against hepatitis B virus and human immunodeficiency virus.
Hookipa has completed the first research milestone by designing and delivering 14 research-grade vectors to Gilead, along with the characterization of these vectors and delivery of a data package for the HIV program.
Pursuant to the terms of the agreement, Hookipa is entitled to a sizeable milestone payment from Gilead.
Under the terms of the agreement, Gilead provided an upfront payment of USD 10m and will fund all research and development activities.
Hookipa will be eligible to receive milestone payments based upon the achievement of specified development, regulatory, and commercial milestones up to a total of approximately USD 400m. HOOKIPA will also be eligible to receive tiered royalties on net sales.
Hookipa Pharma is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system.
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results